reports
- Guy Sips
- Mathijs Geerts Danau
- Mathijs Geerts Danau
mdxhealth Data from the ProMPT study shows predictive value of GPS tes...
At EAU 2026, mdxhealth presented data from Oxford's ProMPT study, demonstrating that the GPS test successfully stratifies the risk of treatment failure across treatment cohorts. The results showed high six-year freedom-from-failure rates. Mdxhealth and Oxford will continue their collaboration through the recently initiated ProtecT-GPS study, with management expecting data read-outs in 2026/2027. We believe these data could support future market share gains for GPS mdx and could help expand the m...
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the...
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – March 16, 2026 () – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that new data demonstrating the prognostic value of the Genomic Prostate Sco...
- Guy Sips
- Hilde Van Boxstael
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Mathijs Geerts Danau
mdxhealth FY25 revenues slightly below preliminary figures but guidanc...
mdxhealth's 4Q25 revenues come in $ 1m lower than the preliminary revenue figures shared in January ($ 30.5m). However the company maintains FY26 revenue guidance of $ 137-140m, implying 27-30% year-over-year revenue growth in FY26. Management also reiterated expectations for continued operating leverage, with a limited increase in OPEX despite significant revenue growth. As a result, mdxhealth expects to achieve a 10% adj. EBITDA run-rate by YE26. We reiterate our BUY and $ 6 TP.
Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Result...
Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – February 26, 2026 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025. Michael K. McGarrity, CEO of mdxhealth, comme...
- Guy Sips
- Mathijs Geerts Danau
- Wim Hoste
- Mathijs Geerts Danau
mdxhealth ExoDx boosts 2026 growth expectations
Following mdxhealth preliminary 2025 full-year sales and 2026 sales guidance in the $ 137-140m range, we update our model and raise 2026 revenue estimates to $ 139.9m, driven by ExoDx and synergy potential with the GPS test. The ExoDx acquisition should ensure the company's high growth profile, and the increased scale should allow for further operational leverage. That said, we note that the company will likely require additional funding to cover cash outflow obligations. Given the high growth o...
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Resul...
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – February 12, 2026 () – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. Title...
- Guy Sips
- Michiel Declercq
- Guy Sips
Biotalys Model update after strategic refocus
We updated our model (New “Accumulate”, New € 5.1 TP) after Biotalys plans a strategic refocus, concentrating resources on its top-priority biofungicide programs. Early-stage activities will be suspended and the organization downsized to cut costs while they claim “protecting long-term platform value”. The shift prioritizes Evoca NG, BioFun-6, and already partnered programs with the Gates Foundation and Syngenta. These measures aim to reduce cash burn by €20m through 2028 and strengthen commerci...
- Guy Sips
Biotalys Refocusing strategy on lead assets and cutting annual cash bu...
We will update our model (from “Buy” to “under review”) after Biotalys plans a strategic refocus, concentrating resources on its top-priority biofungicide programs. Early-stage activities will be suspended and the organization downsized to cut costs while protecting long-term platform value. The shift prioritizes EVOCA NG, BioFun-6, and already partnered programs with the Gates Foundation and Syngenta. These measures aim to reduce cash burn by €20m through 2028 and strengthen commercialization r...
- Guy Sips
Biotalys Ending collaboration with Novonesis, new partnership with 21s...
Biotalys has entered into a strategic partnership with 21st.BIO to accelerate the production of Biotalys' protein-based biocontrol solutions. Biotalys indicated that this collaboration will leverage 21st.BIO's proprietary fermentation platform to support the production of Biotalys' AGROBODY agricultural biocontrol products at commercially competitive costs. We regret that Biotalys and Novonesis will conclude their collaboration (in line with the transition to this new agreement). Biotalys will...
- Guy Sips
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Wim Hoste
- Mathijs Geerts Danau
mdxhealth FIRST LOOK: FY25 highlights show revenue in line with guidan...
Mdxhealth provides insights into key FY25 parameters, with preliminary revenue landing at $ 109m (VA CSS: $ 108.5m) and YE cash at $ 29m (VA CSS: $ 34.5m). Revenue guidance for FY26 is set at a narrow yet ambitious range of $ 137-140m, implying a 26-28% y/y increase. Additionally, mdxhealth managed to amend the Exact Sciences payouts to be more back-end loaded bringing some ease to the cash position. We believe that mdxhealth is well-positioned for growth in 2026 now that the commercial engine i...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenu...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA – January 12, 2026 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2025 revenues and issued 2026 revenue guidance. The Company expects to report fourth quarter and full yea...
- Jacob Mekhael
mdxhealth Collaboration with Oxford could further validate GPS in pros...
Yesterday before US market opens, mdxhealth announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). This study is designed to establish GPS as the first genomic classifier supported by randomised clinical trial evidence in an Active Surveillance cohort, further validating the clinical utility of GPS in predicting prostate cancer progressi...
- Jacob Mekhael
- Livio Luyten
Mdxhealth and University of Oxford to validate GPS test in largest ran...
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 () – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the l...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.